Information Provided By:
Fly News Breaks for January 10, 2020
PTLA
Jan 10, 2020 | 06:41 EDT
Oppenheimer analyst Jay Olson downgraded Portola Pharmaceuticals to Perform from Outperform with a price target of $17, down from $40. The company announced Q4 Andexxa revenues below expectations with commentary describing certain headwinds, Olson tells investors in a research note. The Q4 addition of 90 new hospitals ordering Andexxa fell well below the analyst's 125 estimate. He reduced his estimates to reflect the Andexxa headwinds and downgraded Portola.
News For PTLA From the Last 2 Days
There are no results for your query PTLA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.